U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
On April 10th, 2020
Pfizer Inc.
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA)
has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as
ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer
(CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after
prior therapy.1 The approval is based on results from the BEACON CRC trial, the
only Phase 3 trial to specifically study patients with previously treated
metastatic CRC with a BRAFV600E mutation.
See their press release below for more information:
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy.1 The approval is based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAFV600E mutation.
See their press release below for more information:
No comments have been posted yet.